<p>/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) 是一家致力于靶向治疗药物发现和开发的精准医学肿瘤公司，今天宣布，在 2026 年 2 月 26 日，IDEAYA 董事会的薪酬委员会向三名新聘员工授予了总计 346,200 股公司普通股的非合格股票期权。这些股票期权是根据 IDEAYA Biosciences, Inc. 2023 年就业诱导激励奖励计划（2023 Inducement Plan）授予的，作为这些个人与 IDEAYA 签订雇佣合同的诱因，符合纳斯达克上市规则 5635(c)(4)。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/820568/IDEAYA_v2_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/820568/IDEAYA_v2_Logo.jpg"/></p>
<p>2023 年诱导计划专门用于向之前未曾是 IDEAYA 员工的个人授予股权奖励，或在经过真实的非就业期后，作为这些个人与 IDEAYA 签订雇佣合同的诱因，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>股票期权的行使价格为每股 31.90 美元，等于授予日 IDEAYA 普通股在纳斯达克全球精选市场的收盘价。股票期权的有效期为 10 年，将在四年内逐步归属，其中 25% 的期权将在归属开始日期的第一周年时归属，其余 75% 的期权将在接下来的三年内按月均匀归属。股票期权的归属需依赖于员工在每个归属日期继续为 IDEAYA 服务。</p>
<p><strong>关于 IDEAYA Biosciences</strong> IDEAYA 是一家精准医学肿瘤公司，致力于发现、开发和商业化变革性癌症疗法。我们的做法结合了小分子药物发现、结构生物学和生物信息学的专业知识，以及在识别和验证转化生物标志物方面的强大内部能力，以开发与疾病的遗传驱动因素相一致的量身定制的潜在首创靶向疗法。我们建立了一个深厚的产品候选管道，专注于合成致死性和抗体药物偶联物（ADCs），用于分子定义的实体肿瘤适应症。我们的使命是带来下一波更具选择性、更有效且深度个性化的精准肿瘤治疗，旨在改变疾病进程并改善癌症患者的临床结果。</p>
<p><strong>投资者和媒体联系</strong></p>
<p>IDEAYA Biosciences</p>
<p>Joshua Bleharski, Ph.D.</p>
<p>首席财务官</p>
<p>investor@ideayabio.com</p>
<p>来源：IDEAYA Biosciences, Inc.</p>

IDYA

<p>IDEAYA Biosciences, Inc.（纳斯达克代码：IDYA）宣布根据其 2023 年员工诱导激励奖励计划向三名新员工授予 346,200 股非合格股票期权。该授予符合纳斯达克上市规则 5635(c)(4)，行使价格为每股 31.90 美元。这些期权将在四年内逐步归属，其中 25% 在一年后归属，其余部分按月分期归属。IDEAYA 专注于通过精准医疗开发靶向癌症疗法</p>

<p>, /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on February 26, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 346,200 shares of the Company's common stock to three newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) 是一家致力于靶向治疗药物发现和开发的精准医学肿瘤公司，今天宣布，在 2026 年 2 月 26 日，IDEAYA 董事会的薪酬委员会向三名新聘员工授予了总计 346,200 股公司普通股的非合格股票期权。这些股票期权是根据 IDEAYA Biosciences, Inc. 2023 年就业诱导激励奖励计划（2023 Inducement Plan）授予的，作为这些个人与 IDEAYA 签订雇佣合同的诱因，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/820568/IDEAYA_v2_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/820568/IDEAYA_v2_Logo.jpg"/></p>
<p>The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>2023 年诱导计划专门用于向之前未曾是 IDEAYA 员工的个人授予股权奖励，或在经过真实的非就业期后，作为这些个人与 IDEAYA 签订雇佣合同的诱因，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The stock options have an exercise price of $31.90 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.</p>
<div class="lb-trans"><p>股票期权的行使价格为每股 31.90 美元，等于授予日 IDEAYA 普通股在纳斯达克全球精选市场的收盘价。股票期权的有效期为 10 年，将在四年内逐步归属，其中 25% 的期权将在归属开始日期的第一周年时归属，其余 75% 的期权将在接下来的三年内按月均匀归属。股票期权的归属需依赖于员工在每个归属日期继续为 IDEAYA 服务。</p>
</div><p><strong>About IDEAYA Biosciences</strong> IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.</p>
<div class="lb-trans"><p><strong>关于 IDEAYA Biosciences</strong> IDEAYA 是一家精准医学肿瘤公司，致力于发现、开发和商业化变革性癌症疗法。我们的做法结合了小分子药物发现、结构生物学和生物信息学的专业知识，以及在识别和验证转化生物标志物方面的强大内部能力，以开发与疾病的遗传驱动因素相一致的量身定制的潜在首创靶向疗法。我们建立了一个深厚的产品候选管道，专注于合成致死性和抗体药物偶联物（ADCs），用于分子定义的实体肿瘤适应症。我们的使命是带来下一波更具选择性、更有效且深度个性化的精准肿瘤治疗，旨在改变疾病进程并改善癌症患者的临床结果。</p>
</div><p><strong>Investor and Media Contact</strong></p>
<div class="lb-trans"><p><strong>投资者和媒体联系</strong></p>
</div><p>IDEAYA Biosciences</p>
<div class="lb-trans"><p>IDEAYA Biosciences</p>
</div><p>Joshua Bleharski, Ph.D.</p>
<div class="lb-trans"><p>Joshua Bleharski, Ph.D.</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官</p>
</div><p>investor@ideayabio.com</p>
<div class="lb-trans"><p>investor@ideayabio.com</p>
</div><p>SOURCE IDEAYA Biosciences, Inc.</p>
<div class="lb-trans"><p>来源：IDEAYA Biosciences, Inc.</p>
</div>

IDEAYA Biosciences 宣布根据纳斯达克上市规则 5635(c)(4) 授予诱导性股票期权 | IDYA 股票新闻